Vaccine (Peptide vaccine) · Immune activation, directed at cytomegalovirus antigens
Phase 1/2Most advanced trial (none active)
What is PEP-CMV Vaccine?
PEP-CMV is a peptide vaccine derived from cytomegalovirus antigens. Intradermal administration is intended to stimulate helper and cytotoxic T-lymphocyte responses against CMV-infected tumor cells. It is studied in diffuse midline glioma, medulloblastoma and ependymoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Drug type
Vaccine (Peptide vaccine)
Targets
cytomegalovirus antigens (antigen)
Mechanism
Immune activation, directed at cytomegalovirus antigens
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.